bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell… Read more
bioAffinity Technologies, Inc. (BIAF) - Total Assets
Latest total assets as of September 2025: $11.55 Million USD
Based on the latest financial reports, bioAffinity Technologies, Inc. (BIAF) holds total assets worth $11.55 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
bioAffinity Technologies, Inc. - Total Assets Trend (2019–2024)
This chart illustrates how bioAffinity Technologies, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
bioAffinity Technologies, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
bioAffinity Technologies, Inc.'s total assets of $11.55 Million consist of 41.4% current assets and 58.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.0% |
| Accounts Receivable | $1.14 Million | 17.5% |
| Inventory | $27.61K | 0.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $775.14K | 11.9% |
| Goodwill | $1.40 Million | 21.6% |
Asset Composition Trend (2019–2024)
This chart illustrates how bioAffinity Technologies, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: bioAffinity Technologies, Inc.'s current assets represent 41.4% of total assets in 2024, a decrease from 93.7% in 2019.
- Cash Position: Cash and equivalents constituted 17.0% of total assets in 2024, down from 87.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 32.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 21.6% of total assets.
bioAffinity Technologies, Inc. Competitors by Total Assets
Key competitors of bioAffinity Technologies, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
bioAffinity Technologies, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - bioAffinity Technologies, Inc. generates 1.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - bioAffinity Technologies, Inc. is currently not profitable relative to its asset base.
bioAffinity Technologies, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.65 | 1.02 | 0.01 |
| Quick Ratio | 3.64 | 1.01 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.25 Million | $ 57.97K | $ -11.00 Million |
bioAffinity Technologies, Inc. - Advanced Valuation Insights
This section examines the relationship between bioAffinity Technologies, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.57 |
| Latest Market Cap to Assets Ratio | 0.78 |
| Asset Growth Rate (YoY) | -20.8% |
| Total Assets | $6.51 Million |
| Market Capitalization | $5.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values bioAffinity Technologies, Inc.'s assets below their book value (0.78 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: bioAffinity Technologies, Inc.'s assets decreased by 20.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for bioAffinity Technologies, Inc. (2019–2024)
The table below shows the annual total assets of bioAffinity Technologies, Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.51 Million | -20.77% |
| 2023-12-31 | $8.22 Million | -32.51% |
| 2022-12-31 | $12.18 Million | +738.23% |
| 2021-12-31 | $1.45 Million | +898.12% |
| 2020-12-31 | $145.60K | -77.90% |
| 2019-12-31 | $658.81K | -- |